Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
45–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patient is an ambulatory female 45 years of age or older
Postmenopausal women with diagnosis of osteoporosis
Prescription of zoledronic acid or any OBP as per the current Canadian monograph
Must provide informed consent
You may not be if
Any prior use of iv bisphosphonates within the last 2 years
Known secondary osteoporosis of any aetiology (hypogonadism in premenopausal women or premature menopause, malabsorption, chronic liver disease, inflammatory bowel disease)
Metabolic bone diseases such as primary or secondary hyperparathyroidism, hypoparathyroidism, Paget's disease of bone, Fibrous dysplasia..
Non-corrected hypocalcaemia at the time of zoledronic acid infusion
Creatinine clearance \< or = 30 ml/min
Unwillingness or inability to comply with the study requirements
Concurrent participation in a clinical trial of an investigational drug, or within the last 30 days
